Commission approves first oral GLP-1 agonist for obesity and overweight patients in the EU

09:38 by Wendy WINN (DG SANTE, European Commission)

The oral 25 mg pill has been cleared for treating adults who are considered clinically obese with a Body Mass Index (BMI) of 30 or more, as well as adults who are considered overweight with a BMI of 27 or over. This pill formulation of the weight-loss therapy Wegovy was recommended for approval...

Register to the Health Policy Platform

See full publication (Platform members only)